Skip to content

Author

M. Wiesweg

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Subclinical pulmonary embolism in first-line/induction therapy of lung cancer - a remaining clinically relevant adverse event

Introduction Pulmonary embolism (PE) at initial diagnosis and during first-line systemic treatment is clinically relevant in patients with lung cancer. However, real-world incidence of subclinical PE is not well established. Methods Retrospective single-center analysis of patients at least 18 years old with non-small-c...

Kristin Mersmann, M. Metzenmacher, G. Zaun et al. · 0 citations
Open access Sep 2026

Real-world survival benefit of adding durvalumab to chemotherapy in cholangiocarcinoma: a retrospective cohort analysis from a German Comprehensive Cancer Centre

Background Advanced biliary tract cancers (BTCs) carry a poor prognosis. Gemcitabine/platinum chemotherapy was the first-line standard until TOPAZ-1 and KEYNOTE-966 established immune checkpoint inhibitor-based combinations as a new standard. Real-world data with a chemotherapy-only comparator remain limited. Patients...

S. Elbasan, S. Kasper, I. Mavroeidi et al. · 0 citations
Open access Jul 2026

LLM-Generated Lay-Language Protocols for Molecular Tumor Board Patients: Evaluation of Quality and Clinical Usability

The low paragraph-level error rate and favorable PPEE suggest that structured open-weight LLM generation may be a useful drafting support in a clinician-supervised setting, and a proposed evaluation framework for patient-facing text generation is developed.

T. Pakull, Noëlle Bender, Sven Benson et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.